LIPF (lipase F, gastric type) is a gastric lipase that catalyzes hydrolysis of triacylglycerols into free fatty acids, diacylglycerols, monoacylglycerols, and glycerol, with preferential activity at the sn-3 position of triacylglycerols 12. In gastric tissue, LIPF serves as a chief cell marker and participates in normal lipid metabolism 3. LIPF expression is significantly decreased in gastric cancer compared to normal tissue (59.1% vs 94.4% of samples) 4. This downregulation is particularly associated with a gastric cancer subtype characterized by chief cell markers and activated Wnt/β-catenin signaling 3. Reduced LIPF expression correlates with poor prognosis, including increased local invasion and advanced disease stage, and its expression is linked to lymph node metastasis status 4. LIPF is upregulated in gastric cancers with bone metastasis, where it serves as a chief cell-enriched gene marker associated with worse overall survival 5. The gene undergoes recurrent indel mutations in gastric carcinomas, targeting noncoding regulatory regions and representing a lineage-specific mutational process 6. Clinically, LIPF shows promise as a non-invasive serum biomarker for early gastric cancer diagnosis when combined with other proteins (COL10A1, GKN1, GKN2, REG4), achieving an AUC of 0.890 in controls versus early gastric cancer 7. These findings suggest LIPF dysfunction may represent both a diagnostic and prognostic marker in gastric malignancy.